- Home
- VRM vs CANF Comparison
VRM vs CANF Comparison
Compare VRM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRM
- CANF
- Stock Information
- Founded
- VRM 2012
- CANF 1994
- Country
- VRM United States
- CANF Israel
- Employees
- VRM N/A
- CANF N/A
- Industry
- VRM Other Specialty Stores
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- VRM Consumer Discretionary
- CANF Health Care
- Exchange
- VRM Nasdaq
- CANF Nasdaq
- Market Cap
- VRM 12.7M
- CANF 14.4M
- IPO Year
- VRM 2020
- CANF N/A
- Fundamental
- Price
- VRM $6.57
- CANF $2.07
- Analyst Decision
- VRM
- CANF Strong Buy
- Analyst Count
- VRM 0
- CANF 2
- Target Price
- VRM N/A
- CANF $14.00
- AVG Volume (30 Days)
- VRM 43.9K
- CANF 70.9K
- Earning Date
- VRM 11-12-2024
- CANF 11-19-2024
- Dividend Yield
- VRM N/A
- CANF N/A
- EPS Growth
- VRM N/A
- CANF N/A
- EPS
- VRM N/A
- CANF N/A
- Revenue
- VRM $637,856,000.00
- CANF $667,000.00
- Revenue This Year
- VRM $23.82
- CANF $409.56
- Revenue Next Year
- VRM $25.77
- CANF N/A
- P/E Ratio
- VRM N/A
- CANF N/A
- Revenue Growth
- VRM 16.43
- CANF N/A
- 52 Week Low
- VRM $5.00
- CANF $1.83
- 52 Week High
- VRM $76.96
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- VRM 34.02
- CANF 38.31
- Support Level
- VRM $6.09
- CANF $2.04
- Resistance Level
- VRM $9.25
- CANF $2.21
- Average True Range (ATR)
- VRM 0.62
- CANF 0.19
- MACD
- VRM -0.21
- CANF -0.03
- Stochastic Oscillator
- VRM 35.18
- CANF 7.69
About VRM Vroom Inc.
Vroom Inc is an end-to-end e-commerce platform for the used vehicles industry. The Company's scalable, data-driven technology brings all phases of the car buying and selling process to consumers offering an extensive selection of used vehicles, transparent pricing, competitive financing, and at-home pick-up and delivery. Its three reportable segments are: The E-commerce segment represents retail sales of used vehicles through its e-commerce platform and fees earned on sales of value-added products associated with those vehicle sales, The Wholesale segment represents sales of used vehicles through wholesale channels, and The Retail Financing segment represents UACC's operations with its network of third-party dealership customers.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).